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Abstract 
Background: Accurate childhood cancer survival estimates are critical for policy-makers and clinicians 
for priority-setting and planning decisions. However, observed survival estimates are lacking for many 
countries, and where available, wide variation in outcomes is reported. Understanding the barriers to 
optimizing survival can help improve childhood cancer outcomes. We aimed to provide estimates of 
global childhood cancer survival, accounting for the impact of multiple factors that influence cancer 
outcomes.  
Methods: We developed a microsimulation model to simulate childhood cancer survival for 200 
countries/territories worldwide, taking into account clinical and epidemiologic factors, including 
country-specific treatment variables, such as availability of chemotherapy/radiation/surgery. To ensure 
model results were consistent with reported survival data, we calibrated the model to estimates from 
the CONCORD 2 and 3 studies using an Approximate Bayesian Computation approach. We estimated 
five-year net survival for diagnosed childhood cancer cases in each country/territory and estimated 
potential survival gains if seven policy interventions focused on improving treatment availability and 
delivery were implemented in isolation or as packages. 
Findings: Our model estimates that global five-year net childhood cancer survival is currently 37·4% 
(95% uncertainty interval [UI] 34·7%-39·8%), with large variation by region, ranging from 8·1% (95% UI 
4·4%-13·7%) in Eastern Africa to 83·0% (95% UI 81·6%-84·4%) in North America. Among the seven policy 
interventions modeled, each individually provided limited gains, increasing global five-year net survival 
to between 38·4% and 44·6%. When bundled into packages of interventions that either improved 
service delivery or expanded treatment access, five-year net survival increased to 50·2% (95% UI 47·3%-
53·0%) and 54·1% (95% UI 50·1%-58·5%), respectively. A comprehensive systems approach consisting of 
all policy interventions yielded super-additive gains with global five-year net survival of 53·6% (95% UI 
51·5%-55·6%) at 50% scale-up and 80·8% (95% UI 79·5%-82·1%) at full implementation.  
Interpretation: Childhood cancer survival varies widely by region, with especially poor survival in Africa. 
While expanding access to treatment (chemotherapy/radiation/surgery) and addressing financial 
toxicity are essential, investments that improve the quality of care, at both the health system and 
facility-level, are needed to improve childhood cancer outcomes globally. 
Funding: Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public 
Health, Harvard Medical School, National Cancer Institute, SickKids, St. Jude Children’s Research 
Hospital, Union for International Cancer Control, Children with Cancer UK Davidson and O’Gorman 
Fellowship 
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Research in context 
Evidence before this study 
Recent population-based observed data of five-year net childhood cancer survival (ages 0-14 years) for 
acute lymphoblastic leukemia, lymphomas, and brain tumors from 322 cancer registries globally are 
provided by the CONCORD-3 study. The CONCORD-2 study previously provided similar population-based 
five-year net survival estimates for both acute lymphoblastic leukemia and acute myeloid leukemia. We 
searched PubMed for studies on global childhood cancer survival using the search terms “childhood 
cancer”, “survival”, and “global” on Feb 28, 2019, without language or publication date restrictions. We 
found no other estimates of global childhood cancer survival. While limited observed data from low- and 
lower middle-income countries are available, it is clear that reported survival varies considerably by 
region. 
 
Added value of this study 
With major geographic and histologic gaps in the observed five-year net survival statistics, there are no 
global estimates of how many children survive cancer. This study provides, to our knowledge, the first 
estimate of global childhood cancer survival, based on a simulation model for 200 countries and 
territories and 48 cancer diagnoses. We provide global, regional, and country-level estimates of five-
year net cancer survival for all International Classification of Childhood Cancer (Third edition) subgroups 
and estimate the potential impact of various policy scenarios to help guide priority-setting efforts aimed 
at improving survival. 
 
Implications of all the available evidence 
The estimated gap in childhood cancer five-year net survival between high-income and low-income 
countries is over 70 percentage points. Thus, the most important prognostic factor for whether a child 
will survive cancer is where he or she lives. Our model-based findings suggest that while improving the 
availability of treatments and mitigating abandonment are necessary interventions to achieve high 
survival, they are insufficient if implemented alone.  Concurrent improvements in health systems to 
achieve better quality of care will also be needed to substantially improve childhood cancer survival 
worldwide. 
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Background 1 
Advances in treatment and supportive care over the past six decades have led to increases in five-year net 2 
survival for children diagnosed with cancer (ages 0-14 years) from nearly 0% to 80% in high-income 3 
countries (HIC) like Great Britain.1 While it is generally known that children who develop cancer in low-4 
income and middle-income countries (LMIC) have not experienced these gains,2 the magnitude of the 5 
overall survival gap has not been quantified. The best available data, as observed in global population-6 
based cancer registries, was recently published by the CONCORD study for a subset of childhood cancers: 7 
acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphomas (as a group), and brain 8 
tumors.3-5 9 
Highlighting the survival gap, CONCORD estimates of five-year net survival for ALL, the most common 10 
childhood cancer, range from less than 10% to over 90%.5 However, due to the paucity of cancer registry 11 
data from resource-limited settings, only a small subset of CONCORD-3 data (7/322 registries) are from low-12 
income and lower middle-income countries. Disparities in treatment access,6 quality,2 and financial toxicity7 13 
all contribute to the large global variations in childhood cancer outcomes.2-5,8,9 14 
In order to quantify the survival gap and identify opportunities for intervention, we developed a simulation 15 
model that synthesizes clinical, epidemiologic, and health system data to estimate country-specific 16 
childhood cancer survival. Using the model, we estimate the potential survival gains that could be achieved 17 
by addressing barriers to successful treatment, such as availability of treatment modalities and quality of 18 
care. These estimates will be used to inform the Lancet Oncology Commission on Sustainable Paediatric 19 
Cancer Care, and can assist decision-makers as they prioritize policy interventions that have the potential to 20 
improve survival and reduce the number of deaths from childhood cancer.  21 
 22 
Methods 23 
Study design and data sources 24 
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We developed the Global Childhood Cancer (GCC) microsimulation model to simulate childhood cancer 25 
incidence10 and survival for 200 countries/territories for 48 cancer subcategories defined by the 26 
International Classification of Childhood Cancer, Third edition (ICCC).11 The survival module of the GCC 27 
model, described here, simulates the clinical course of childhood cancer from diagnosis to five years post-28 
diagnosis, taking into account treatment availability, completion, and quality.  29 
We fit the model to observed data by calibrating our model parameters so that our predicted survival 30 
estimates were consistent with population-based survival estimates for each cancer and country produced 31 
for this study by the CONCORD programme for the global surveillance of cancer survival.3-5 We then used a 32 
hierarchical approach to infer parameters for countries/diagnoses for which no survival data are available. 33 
Using the calibrated model, we estimated current childhood cancer survival for all countries and projected 34 
survival gains from expanding access to each treatment modality and improving quality of care. We briefly 35 
describe our methods below and provide full details in the appendix. 36 
 37 
Procedures 38 
We developed a conceptual treatment cascade to account for multiple factors that impact cancer survival 39 
from the point of diagnosis to completion of therapy (Figure 1).  We assume that a subset of children 40 
diagnosed with cancer will achieve five-year survival based on the availability, completion, and quality of 41 
treatment. If any required treatment modalities (chemotherapy/radiation/surgery) are unavailable, we 42 
assume the child will not survive. We also include a risk of abandoning treatment due to financial toxicity 43 
(i.e. financial distress related to the cost of medical care). Lastly, we assume that the quality of care, which 44 
depends on a functioning health system with supportive services (e.g. nursing standards, integrated referral 45 
and record-keeping) and facility-level activities (e.g. infection control, nutritional support), influences 46 
survival. We synthesized information from multiple sources to inform country-specific estimates for each 47 
step of the cascade (Table 1). 48 
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We used published estimates of diagnosed cancer cases by country and ICCC category from the GCC 49 
Incidence module.10 These estimates, which take into account geographic variation in cancer incidence and 50 
country-specific factors such as demographic trends and health system barriers, are consistent with 51 
reported rates of diagnosed cancers in the International Incidence of Childhood Cancer, Volume III (IICC-52 
3).12 The GCC Incidence module also provides estimates for countries without registries. 53 
For each ICCC diagnosis, we used expert opinion (based on the experience of clinicians with expertise in 54 
cancer care in LMIC and specializing in different cancer types (e.g. hematologic cancers, germ cell tumours, 55 
solid tumors, etc.))  to specify which treatment components (chemotherapy/radiation/surgical specialties) 56 
were necessary for survival. Because stage at diagnosis (which determines necessary treatments for some 57 
cancers) is not routinely collected in most cancer registries, as a proxy we estimated the probability of 58 
requiring chemotherapy/radiation based on reported treatment numbers from the Surveillance, 59 
Epidemiology, and End Results (SEER) program in the US. We also took into account heterogeneity in 60 
treatment needs for diagnoses for which a small proportion of patients require chemotherapy/radiation 61 
(Appendix  pg 3-5).  62 
To account for the curability of different cancer types we estimated maximum achievable survival 63 
probabilities using data from SEER 2010-2014 to inform the general level and variation of survival by 64 
diagnosis.13 Because maximum achievable survival in the model assumes availability of all necessary 65 
treatment modalities, no abandonment, and optimal quality of care, we inflated the reported SEER 66 
estimates to account for the possibility of non-optimal service delivery in the US (Appendix  pg 6-7).  67 
As calibration targets we obtained country-specific survival estimates for 10 morphology groups from 68 
CONCORD (Appendix  pg 8).3,5 For three brain diagnoses (Astrocytoma, Embryonal, and Other), the 69 
CONCORD estimates of survival in the US were substantially higher than those reported in SEER. 70 
Specifically, SEER estimates of five-year survival were 80%, 68·4%, and 58·9%, respectively, compared to 71 
CONCORD estimates of 82·7%, 69·4%, and 96·9%. We therefore adjusted our prior probability distributions 72 
of maximum achievable survival for these groups to be consistent with the CONCORD estimates. 73 
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We used published country-specific estimates to inform the prior probability distributions of treatment 74 
variables in the model (Table 1). We estimated priors of the availability of chemotherapy agents based on 75 
reported data from a global survey of paediatric oncologists (Appendix  pg 10-11).6 Estimates of 76 
radiotherapy availability were based on coverage estimates from the Lancet Radiotherapy Commission 77 
(Appendix  pg 12-13).14 78 
Data for surgical specialties were drawn from multiple sources. For general surgery, we used estimates 79 
from a modeling study of the Lancet Surgery Commission (Appendix  pg 14-15).15 For neurosurgery, we 80 
used data on neurosurgeon density from the World Federation of Neurosurgical Societies (Appendix  pg 16-81 
17).16 Finally, for ophthalmic surgery we used data on the density of ophthalmologists from the World 82 
Council of Ophthalmologists (Appendix  18-19).17 When sampling country-specific surgery probabilities we 83 
assumed that general surgery was the most available type of surgery, followed by ophthalmic surgery, with 84 
neurosurgery the least likely to be available.  85 
To estimate probabilities of treatment abandonment we used published data from a global survey of 86 
paediatric oncologists (Appendix  pg 20-21).7 We assumed that only patients requiring chemotherapy 87 
and/or radiation (thus excluding the few surgery-only groups) were at risk of abandoning treatment due to 88 
the prolonged nature of these modalities.  89 
Lastly, we included a parameter for ‘quality of care’, which has been defined as the “degree to which health 90 
services for individuals and populations increase the likelihood of desired health outcomes and are 91 
consistent with current professional knowledge”.18 This parameter allows us to account for health system 92 
and facility-level factors, capturing residual differences in survival not explained by treatment access or 93 
abandonment (Appendix  pg 22-23).  94 
We used a modified Bayesian hierarchical framework19 with three levels (World Bank income group, region, 95 
country) to synthesize all available estimates to generate prior probability distributions for all parameters 96 
described above. This approach allowed us to regularize the reported data and estimate priors for countries 97 
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with no data (see Appendix  pg 24 for more details). These priors were used as initial sampling distributions 98 
during calibration. 99 
 100 
Outcomes 101 
For each country and territory, we modeled the effect of treatment variables on childhood cancer 102 
outcomes and estimated five-year net survival for each ICCC diagnosis. We also estimated what five-year 103 
net survival would be under various policy interventions aimed at improving survival. We report the mean 104 
and 95% uncertainty intervals (UI) calculated as the 2·5 and 97·5 percentiles of our simulation results.  105 
 106 
Statistical analysis 107 
Calibration involves comparing model predictions with observed data to identify parameter values that 108 
achieve a good fit.20 We briefly describe this process here (see Appendix  pg 25-56 for full details). 109 
We calibrated to CONCORD country/diagnosis-specific five-year net survival estimates, providing 407 110 
targets for model calibration. CONCORD-3 estimates of AML survival were reserved as a test set to assess 111 
model validity and were not used in calibration. We used an Approximate Bayesian Computation (ABC) 112 
approach to fit each country with CONCORD data (65 countries).21 For each sampled parameter set we 113 
simulated five-year net survival for the number of cancer cases reported for each CONCORD estimate. If the 114 
simulated survival probability was within one percentage point of the reported survival estimate we 115 
accepted the sampled parameters as a draw from the posterior distribution as per the ABC algorithm.21 If a 116 
parameter set was not accepted after one million iterations, the best-fitting parameter set for the country 117 
was used. For computational efficiency we used simulated annealing22 to direct the sampling.  118 
For each country, we first tried to fit the model using overall probabilities of chemotherapy availability and 119 
treatment abandonment across cancer diagnoses. If the model was unable to fit after 100,000 iterations we 120 
allowed these probabilities to vary by diagnosis (see Appendix  pg 10-11 and pg 20-21). Automatically 121 
introducing flexibility in this way allowed us to fit parsimonious models where possible, while accounting 122 
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for variability in the availability and efficacy of diagnosis-specific chemotherapy regimens and 123 
abandonment if needed.  124 
After fitting each country with calibration targets, we sampled from the posteriors of the hierarchical 125 
models to generate parameter values for countries with no CONCORD estimates. This approach allowed us 126 
to appropriately reflect country-specific parameter uncertainty while ‘borrowing’ information from similar 127 
countries (i.e. region and income group) when data were not available, similar to approaches used by the 128 
Global Burden of Disease and GLOBOCAN for data imputation.8,9 This set of parameter values for all 129 
countries and cancers comprises a completed parameter set. 130 
We repeated this process to generate 1,000 different parameter sets and scored each set based on how 131 
well the model predictions matched the survival targets (based on the distance squared), with each survival 132 
target weighted inversely proportional to the width of its confidence interval. We selected the top 100 sets 133 
for use in the final model to account for parameter uncertainty. 134 
As a posterior predictive check19 we compared our predicted survival from the final model to the reported 135 
survival estimates from CONCORD. Nearly all (99·0%) of our prediction intervals (i.e. 95% UI) overlapped 136 
with the 95% CIs of the CONCORD data, and our prediction intervals contained the reported point estimate 137 
87·2% of the time. Our mean predicted survival also fell within the CONCORD 95% CIs 86·4% of the time 138 
(Appendix  pg 28-47). 139 
As a further validity check we compared our predictions of AML survival to estimates for 48 countries from 140 
CONCORD-3. These estimates were not used to calibrate the model, so they can serve as an external 141 
validity check of our model predictions. Our prediction intervals (95% UI) overlapped with the CONCORD-3 142 
AML 95% CIs 97·9% of the time, contained the reported point estimate (i.e. coverage probability) 81·3% of 143 
time, and our mean predicted survival fell within the 95% CIs 77·0% of the time (Appendix  pg 54-55).  144 
Using the best-fitting 100 parameter sets we estimated five-year net cancer survival for each diagnosis. We 145 
ran 1,000 simulations from 2015 to 2019 to estimate survival over this period, in each iteration sampling a 146 
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good-fitting parameter set to account for parameter (second-order) uncertainty and simulating the number 147 
of diagnosed cases10 and individual-level survival to account for first-order uncertainty.23  148 
To explore the impact of treatment barriers (treatment availability, abandonment, and quality of care), we 149 
simulated counterfactual interventions in which we replaced the relevant parameter for each country with 150 
the mean estimated parameter among high income countries (Table 2). We also simulated packages of 151 
policy interventions to explore the relative impact of expanding treatment access vs. improving service 152 
delivery, and a comprehensive approach addressing all treatment barriers. We estimated five-year net 153 
childhood cancer survival for each scenario. The GCC model was coded in Java (version 1.8.0), and statistical 154 
analyses were performed in R (version 3.3.1). 155 
 156 
Role of the funding source 157 
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or 158 
writing of the report. All authors had full access to all the data used in the study. The corresponding author 159 
had final responsibility for the decision to submit for publication. 160 
 161 
Results 162 
We estimate that globally, for children diagnosed in 2015, five-year net survival for all cancers combined 163 
was 37·4% (95% UI 34·7%–39·8%), with large variation by region, ranging from 8·1% (95% UI 4·4%–13·7%) 164 
in Eastern Africa to 83·0% (95% UI 81·6%–84·4%) in North America (Figure 2). Detailed survival estimates by 165 
diagnosis and continent for all 48 ICCC categories are presented in Figure 3. These estimates reveal large 166 
variation within cancer-specific survival, with survival gaps of over 80 percentage points for cancers such as 167 
Hodgkin lymphoma and retinoblastoma that have high survival in North America but very poor survival in 168 
Africa. See Appendix pg 57-257 for complete country-/diagnosis-specific survival estimates. 169 
We find that among individual policy interventions, efforts to improve the quality of care could yield the 170 
largest potential survival gains globally (five-year net survival of 44·6% [95% UI 41·7%-47·4%], an increase of 171 
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7·2%), followed by expanding access to general surgery (42·7% [95% UI 39·9%-45·6%], 5·3% increase) and 172 
chemotherapy (41·9% [95% UI 38·9%-45·0%], 4·5% increase) (Table 3). This general pattern is similar across 173 
most regions of the world.  174 
Looking at policy intervention packages, we find that increasing the availability of all treatments to the level 175 
of HIC has a significant, though still relatively modest effect on global five-year net survival (54·1% [95% UI 176 
50·1%-58·5%]). Similarly, improving service delivery (i.e. simultaneously improving quality of care and 177 
reducing abandonment) yields important survival gains, but to a lesser extent (50·2% [95% UI 47·3%-178 
53·0%]).We see however that improving both treatment access and service delivery has a super-additive 179 
effect. For example, closing the gap with HIC for all components by 50% is predicted to achieve similar or 180 
larger gains in global five-year net survival (53·6% [95% UI 51·5%-55·6%]) compared to 100% scale-up of 181 
treatment access or service delivery packages separately (Table 3). Full implementation of all interventions 182 
is estimated to increase global five-year net survival to 80·8% (95% UI 79·5%-82·1%). 183 
 184 
Discussion 185 
Using rigorous statistical and computational methods to synthesize estimates from multiple sources of 186 
data, we developed a model of childhood cancer survival for 200 countries/territories worldwide. We find 187 
that childhood cancer survival varies widely by country due to substantial differences in access to 188 
multidisciplinary treatment modalities, abandonment rates, and quality of care. As a result, our findings 189 
suggest that five-year net survival for all childhood cancers combined varies by up to 75 percentage points 190 
between World Health Organization (WHO) sub-regions (Table 3). Furthermore, as net survival only 191 
considers deaths from cancer, the gap in total survival is likely even larger given higher risks of competing 192 
mortality in LMIC. Although genetic variations are known to impact survival,24,25 the most important 193 
prognostic factor today for whether a child diagnosed with cancer will survive is not related to cancer 194 
biology, but is instead the country where they receive treatment.  195 
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Beyond their importance for policy-making and informing health investment decisions by countries and 196 
development agencies, these estimates can provide a baseline assessment to help guide efforts to improve 197 
childhood cancer policies and those aimed at building stronger health systems. For example, the WHO 198 
Global Initiative for Childhood Cancer, announced in September 2018,26 aims to increase global childhood 199 
cancer survival to 60% by 2030, as measured by six tracer cancer subtypes: ALL, Hodgkin lymphoma, Burkitt 200 
lymphoma, retinoblastoma, nephroblastoma, and low-grade gliomas. Our estimates of five-year net 201 
survival for ALL (56·1%) and Hodgkin lymphoma (44·6%) suggest moderate improvement is required for 202 
these cancers to achieve 60% survival. However, our survival estimates for the other cancers are much 203 
lower, with retinoblastoma, Burkitt, and nephroblastoma all around 25% (Figure 3). (It is not possible to 204 
estimate survival for low-grade gliomas with the current ICCC categories.)  205 
In contrast, we estimate five-year net survival for these cancers to be 90% or higher in North America, 206 
highlighting both the opportunity to substantially increase survival and the challenge of achieving these 207 
gains in a relatively short period of time. However, given that nearly half of children with cancer may fail to 208 
be diagnosed in LMIC,10 the true overall survival rate is likely even lower. Therefore, in addition to 209 
improving treatment, increased efforts to identify all cases in a population and develop stronger health 210 
systems with appropriate support services will also be needed to improve survival for all children with 211 
cancer. 212 
To address the stark global disparities in childhood cancer survival, determining which policy interventions 213 
are likely to be most effective is a necessary first step. Individually, our model predicts that single policy 214 
interventions alone will yield limited survival gains. While efforts to address any one problem, such as 215 
financial toxicity, are necessary to achieve high survival, they are insufficient if implemented alone. In 216 
particular, we find that while reducing abandonment results in more children completing therapy, overall 217 
survival does not significantly improve due to interdependencies in the availability of treatment modalities 218 
and quality of care. Although abandonment represents an important actionable opportunity, ensuring 219 
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patient retention and completion of therapy is inefficient if the quality of care is not also improved to 220 
reduce treatment-related toxicity. 221 
Our findings instead highlight the importance of complex interdependencies in childhood cancer treatment. 222 
We find that comprehensive packages of policy interventions that improve both treatment access and 223 
service delivery yield synergistic survival gains. Thus, a key message is that a systems approach with 224 
packages of policy interventions including investments to expand access to multidisciplinary care, reduce 225 
financial toxicity, and improve service delivery are necessary to substantially improve cancer survival. In a 226 
follow-up analysis we are estimating the return on investment of implementing such a comprehensive 227 
approach, taking into account the costs of health system strengthening to improve care for children with 228 
cancer. 229 
Beyond the interdependence of policy interventions, the model also highlights the importance that quality 230 
of care plays in improving childhood cancer outcomes. These findings are not unique to paediatric cancer, 231 
as the importance of quality is echoed in results from other areas of global health as well. For example, a 232 
conditional cash-transfer program incentivizing facility childbirth in India succeeded in substantially 233 
expanding access to healthcare, but failed to reduce maternal mortality due to a lack of focus on quality.27 234 
Similarly, improving childhood cancer outcomes worldwide will require paying attention to what happens 235 
once children reach healthcare facilities, with investments to measure and improve healthcare quality in 236 
addition to expanding access.28  237 
The widespread impact of quality, from the patient level to the health system means that a broad range of 238 
initiatives is needed. For example, at the facility level, supportive care-related interventions (e.g. infection 239 
control and nutritional programs) designed to reduce death due to comorbidities are critical to improve 240 
service delivery and safety. Although generic guidelines promoting the importance of supportive care 241 
measures have been published,29 specific quality improvement initiatives that reflect the local context need 242 
to be designed and evaluated. Improving the quality of care also requires higher-level improvements to the 243 
overall health system (e.g. workforce planning and efficient referral patterns). A focus on quality at all levels 244 
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of the health system is thus needed to achieve integrated care that is person-centered and responsive to 245 
the patient’s needs. 246 
 247 
Limitations 248 
While our modeling approach allows us to synthesize data from multiple sources in a way that is consistent 249 
with data on treatment availability and reported survival, there are a number of limitations due to the 250 
assumptions needed for model development. First, much of our data is based on cross-sectional surveys of 251 
treatment access and abandonment that may provide an incomplete snapshot of the reality on the ground. 252 
For example, our prior probabilities (i.e. pre-calibration) of abandonment are based on survey data which 253 
reported estimates for ALL only,7 and the survey data used to inform chemotherapy priors may not be 254 
representative of the respondents’ countries as a whole. However, our approach allowed us to account for 255 
uncertainty around all model parameters, as well as their joint distribution. Our 95% uncertainty intervals 256 
thus reflect the sensitivity of our results to different parameter estimates. However, it should be noted that 257 
while these intervals capture the statistical uncertainty around the model parameters and calibration 258 
targets, they do not include uncertainty due to other factors, such as our modelling assumptions and 259 
potential data quality issues in the calibration targets used to fit the model. 260 
Second, although we used hierarchical models to incorporate all available observed data, the paucity of 261 
registries in LMIC and small sample sizes in some regions may have affected our results, and contribute to 262 
the wide uncertainty intervals we report for some cancers and countries. For example, CONCORD survival 263 
estimates were only available for two countries in sub-Saharan Africa (Nigeria and Lesotho), and then only 264 
for ALL.  265 
Third, due to lack of data we used a single quality parameter per country as a proxy for many factors 266 
related to service delivery. In some countries this constraint meant it was not possible to fit all calibration 267 
targets. However, our approach allows us to refine and update our model as more specific data become 268 
available. While abstract, our estimates of quality are similar to other published estimates and are highly 269 
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correlated (r=0·83) with the Global Burden of Disease Healthcare Access and Quality Index (HAQI) 270 
(Appendix  pg 56).30 Given that our quality parameters were inferred exclusively by model calibration this 271 
builds confidence in the convergent validity of our estimates. 272 
Lastly, while calibration allowed us to align our model results with observed survival and induce appropriate 273 
covariance between model parameters, due to lack of data we assumed that the availability of each 274 
treatment modality was independent for each individual patient. In the future, facility-level data would 275 
help to refine this assumption and account for correlation between the availability of treatment options for 276 
a given patient. In addition, these types of data could also help inform more specific quality measures to 277 
include in the model to track progress more precisely. 278 
Notwithstanding these limitations, using a model-based approach, we provide, to our knowledge, the first 279 
global estimate of childhood cancer survival and find large disparities in five-year net survival as a result of 280 
substantial differences in access to multidisciplinary treatment modalities, abandonment rates, and quality 281 
of care. Our findings suggest that while increasing access to treatment is necessary to achieve high survival, 282 
it is not sufficient. A comprehensive set of policy interventions, including expanding treatment access, 283 
reducing abandonment, and improving quality of care in health systems are needed to reduce the large 284 
disparities in childhood cancer survival and substantially reduce childhood cancer deaths worldwide.285 
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Table 1: Overview of GCC Survival Module country-specific data sources 
Model 
Parameter 
Data Source 
# Model 
Countries 
Reported 
Reference 
Cancer Diagnosis 
Diagnosed 
cancer cases 
Estimated annual diagnosed cases by 
ICCC subgroup  
200 GCC Incidence Module10  
Cancer Survival 
Necessary 
treatment 
components 
Expert opinion; SEER estimates of 
chemotherapy/radiation used as proxy 
for cancer stage 
1 (US) 
SEER13 
(Appendix  pg 3-5)  
Maximum 
achievable 
survival 
SEER 2010-2014 five-year relative 
survival used as initial proxy 
1 (US) 
SEER13 
(Appendix  pg 6-7) 
Population-
based survival 
Five-year net survival by country, 
derived from cancer registry data 
10-64 (varies 
by diagnosis) 
CONCORD3,5 
(Appendix  pg 8) 
Cancer Treatment 
Chemotherapy 
availability 
Reported availability of chemotherapy 94 
Published survey data6 
(Appendix  pg 10-11) 
Radiation 
availability 
Radiotherapy coverage 173 
Lancet Radiotherapy Commission14 
(Appendix  pg 12-13) 
    
Surgery 
availability 
Availability of general surgery 
 
Neurosurgeon density 
 
Ophthalmologist density 
184 
 
192 
 
192 
Lancet Global Surgery Commission15 
(Appendix  pg 14-15) 
World Federation of Neurosurgical 
Societies16 (Appendix  pg 16-17) 
International Council of Ophthalmology17 
(Appendix  pg 18-19) 
Treatment 
abandonment 
Probability of treatment abandonment  98 
Published survey data7 
(Appendix  pg 20-21) 
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Table 2: Policy Intervention Scenarios 
Scenario Name Description of Policy Intervention 
Baseline (No change from baseline) 
Individual Policy Intervention 
Chemotherapy Increase availability of chemotherapy to mean of HIC 
Radiation Increase availability of radiation to mean of HIC 
General Surgery Increase availability of general surgery to mean of HIC 
Neurosurgery Increase availability of neurosurgery to mean of HIC 
Ophthalmology Increase availability of ophthalmic surgery for Retinoblastoma to mean of HIC 
Abandonment Reduce treatment abandonment to mean of HIC 
Quality of Care Improve quality of care to mean of HIC 
Packages of Policy Interventions 
Expand Treatment 
Access 
Increase availability of all treatment modalities (chemotherapy, radiation, surgery and 
surgical subspecialties) to mean of HIC 
Improve Service 
Delivery 
Improve quality of care while reducing abandonment rates to mean of HIC 
Comprehensive – 
50% 
Expand treatment access and improve service delivery to close the gap with mean of HIC by 
50% 
Comprehensive – 
100%  
Expand treatment access and improve service delivery to close the gap with mean of HIC by 
100% 
HIC = High Income Countries 
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Table 3: Estimated Childhood Cancer Five-Year Net Survival 2015-2019 (%) Under Various Policy Interventions* 
    Single Intervention - Treatment Access 
Single Intervention - 
Service Delivery Intervention Packages 
Area Baseline Chemotherapy Radiation 
General 
Surgery 
Neuro-
surgery 
Ophthalmic 
Surgery 
Abandon-
ment 
Quality of 
Care 
Expand 
Treatment 
Access 
Improve 
Service 
Delivery 
Comprehe
nsive - 
50%+ 
Comprehe
nsive - 
100%+ 
GLOBAL 
37·4 
(34·7-39·8) 
41·9 
(38·9-45·0) 
39·1 
(36·4-41·5) 
42·7 
(39·9-45·6) 
39·0 
(36·3-41·6) 
38·4 
(35·8-40·9) 
41·1 
(37·8-44·4) 
44·6 
(41·7-47·4) 
54·1 
(50·1-58·5) 
50·2 
(47·3-53·0) 
53·6 
(51·5-55·6) 
80·8 
(79·5-82·1) 
Low income 
7·4 
(5·0-10·7) 
10·0 
(6·6-14·5) 
9·4 
(6·4-13·4) 
15·5 
(10·8-20·6) 
7·7 
(5·2-11·1) 
8·6 
(5·9-12·1) 
12·2 
(8·7-16·5) 
14·4 
(11·0-18·2) 
26·5 
(18·3-35·4) 
23·9 
(20·0-27·8) 
29·4 
(25·8-33·4) 
80·6 
(77·2-83·3) 
Lower middle 
income 
24·0 
(19·5-29·1) 
29·2 
(23·4-34·3) 
26·1 
(21·1-31·6) 
31·9 
(26·2-38·2) 
26·0 
(21·1-31·5) 
25·5 
(20·9-30·8) 
28·5 
(22·6-34·8) 
33·6 
(28·7-38·3) 
46·5 
(38·0-53·9) 
40·8 
(36·7-45·3) 
45·4 
(41·7-49·2) 
80·6 
(78·9-82·1) 
Upper middle 
income 
55·5 
(51·5-58·9) 
61·5 
(55·6-67·1) 
56·9 
(52·8-60·5) 
57·4 
(54·1-60·6) 
57·5 
(54·0-60·4) 
55·9 
(52·1-59·2) 
58·4 
(53·7-63·1) 
61·9 
(55·9-68·1) 
68·2 
(61·7-73·5) 
65·2 
(59·5-71·5) 
66·9 
(64·4-69·1) 
80·2 
(78·8-81·6) 
High income 
79·8 
(78·7-80·8) 
80·6 
(79·6-81·7) 
80·0 
(78·9-81·0) 
80·2 
(79·2-81·3) 
80·3 
(79·2-81·3) 
79·9 
(78·8-80·9) 
80·4 
(79·4-81·5) 
80·2 
(79·2-81·3) 
81·7 
(80·7-82·8) 
80·9 
(79·9-81·9) 
81·3 
(80·3-82·4) 
82·9 
(82·0-83·9) 
Africa 
11·6 
(8·7-14·8) 
14·1 
(10·5-18·1) 
13·4 
(10·1-17·1) 
19·0 
(13·9-25·1) 
12·0 
(9·0-15·4) 
13·1 
(9·8-16·9) 
16·2 
(12·0-21·4) 
21·0 
(18·0-24·5) 
29·0 
(21·4-37·6) 
30·4 
(26·8-34·0) 
33·7 
(30·2-37·4) 
80·9 
(77·9-83·5) 
Eastern Africa 
8·1 
(4·4-13·7) 
10·5 
(5·5-17·5) 
10·7 
(5·9-18·0) 
15·3 
(8·7-23·7) 
8·3 
(4·6-14·1) 
8·8 
(4·9-14·7) 
13·0 
(7·5-19·6) 
15·4 
(11·0-20·8) 
26·3 
(14·9-41·9) 
25·1 
(19·6-30·8) 
29·7 
(24·5-36·0) 
80·2 
(75·5-83·4) 
Southern Africa 
19·2 
(11·9-26·1) 
21·7 
(13·9-30·1) 
22·3 
(14·6-30·5) 
22·5 
(14·6-31·4) 
20·4 
(12·8-27·6) 
20·8 
(13·2-28·2) 
23·2 
(15·0-31·0) 
29·4 
(24·8-34·1) 
34·8 
(24·3-53·3) 
36·5 
(32·0-41·1) 
38·3 
(32·7-45·0) 
79·1 
(75·7-81·7) 
Western Africa 
8·5 
(4·9-13·0) 
10·9 
(6·3-17·3) 
9·4 
(5·5-14·4) 
17·3 
(9·7-28·1) 
8·7 
(5·0-13·2) 
10·8 
(6·1-16·7) 
13·5 
(7·1-22·2) 
17·5 
(13·4-23·1) 
26·2 
(15·2-40·3) 
28·1 
(22·8-34·3) 
31·8 
(26·4-38·1) 
82·0 
(78·1-85·0) 
Northern Africa 
30·3 
(18·5-41·6) 
33·9 
(20·3-46·1) 
32·9 
(19·9-45·1) 
34·8 
(20·6-47·7) 
32·0 
(19·5-44·0) 
30·9 
(18·8-42·5) 
33·3 
(20·1-46·7) 
47·0 
(42·0-51·9) 
45·4 
(26·8-62·2) 
51·8 
(47·7-56·1) 
50·3 
(42·2-58·0) 
79·2 
(77·3-81·3) 
Asia 
39·6 
(35·1-43·6) 
45·8 
(40·8-50·8) 
41·6 
(36·7-45·6) 
45·2 
(40·5-50·4) 
41·8 
(37·1-46·4) 
40·6 
(36·1-44·8) 
43·4 
(38·0-48·1) 
46·9 
(42·3-50·9) 
59·8 
(53·9-66·3) 
51·9 
(47·1-56·4) 
56·4 
(53·2-59·3) 
80·1 
(78·9-81·2) 
Eastern Asia 
53·8 
(46·5-59·4) 
61·3 
(51·4-72·3) 
55·2 
(47·4-60·5) 
55·7 
(49·6-60·6) 
55·7 
(49·2-61·3) 
54·3 
(47·3-59·8) 
57·0 
(48·7-65·8) 
59·5 
(49·0-70·8) 
67·9 
(57·5-77·2) 
63·0 
(52·3-73·9) 
65·6 
(61·1-69·1) 
79·4 
(77·5-81·3) 
South-Central 
Asia 
31·3 
(23·2-39·8) 
38·0 
(28·3-46·4) 
33·7 
(25·0-42·1) 
40·2 
(30·7-50·7) 
34·3 
(25·5-44·0) 
32·6 
(24·4-41·3) 
34·8 
(25·9-43·9) 
38·8 
(31·5-49·1) 
58·4 
(46·1-69·4) 
43·5 
(36·7-52·2) 
51·5 
(45·5-57·7) 
80·5 
(79·2-81·9) 
South-Eastern 
Asia 
28·8 
(22·2-35·5) 
33·6 
(25·2-43·1) 
30·7 
(23·6-38·0) 
34·0 
(26·7-41·9) 
30·0 
(23·1-37·0) 
30·1 
(23·2-37·1) 
34·7 
(26·3-43·9) 
39·0 
(33·9-44·1) 
46·9 
(35·6-58·8) 
47·2 
(42·8-51·8) 
48·4 
(43·3-53·8) 
79·3 
(77·5-81·2) 
Western Asia 
56·7 
(51·9-60·7) 
58·7 
(53·0-63·4) 
58·5 
(53·1-62·9) 
58·3 
(53·4-62·8) 
57·8 
(52·9-62·1) 
56·9 
(52·1-61·0) 
60·5 
(54·8-64·9) 
63·8 
(60·7-66·5) 
64·5 
(57·6-70·5) 
68·8 
(66·3-71·3) 
67·1 
(63·9-70·1) 
81·4 
(79·9-82·9) 
Europe 
74·3 
(71·9-76·4) 
75·4 
(72·9-77·5) 
75·2 
(72·6-77·4) 
74·9 
(72·7-76·9) 
75·0 
(72·8-77·0) 
74·4 
(72·0-76·4) 
75·2 
(72·7-77·5) 
76·6 
(74·8-78·3) 
77·9 
(75·4-80·1) 
77·8 
(76·0-79·3) 
77·9 
(76·3-79·4) 
82·2 
(81·0-83·3) 
Eastern Europe 
65·7 
(59·9-70·3) 
67·4 
(61·4-72·5) 
67·5 
(61·1-72·6) 
66·9 
(61·6-71·5) 
67·1 
(61·6-71·7) 
65·9 
(60·2-70·4) 
67·4 
(60·7-72·1) 
70·4 
(66·5-74·3) 
72·4 
(66·5-77·8) 
72·6 
(69·1-76·3) 
72·7 
(69·2-75·9) 
81·3 
(79·5-83·3) 
Northern 
Europe 
80·6 
(78·3-82·7) 
81·1 
(78·9-83·3) 
80·8 
(78·5-82·9) 
80·7 
(78·6-82·8) 
80·8 
(78·6-82·9) 
80·6 
(78·3-82·7) 
80·8 
(78·5-82·9) 
81·0 
(78·7-83·1) 
81·8 
(79·7-83·8) 
81·2 
(79·0-83·4) 
81·5 
(79·5-83·5) 
82·5 
(80·4-84·6) 
Southern 
Europe 
76·2 
(73·9-78·7) 
77·3 
(74·9-79·8) 
76·9 
(74·4-79·5) 
76·5 
(74·3-79·0) 
76·6 
(74·3-79·1) 
76·3 
(74·0-78·7) 
77·2 
(74·7-79·8) 
78·3 
(76·2-80·4) 
78·8 
(76·3-81·5) 
79·4 
(77·2-81·5) 
79·1 
(77·2-81·2) 
82·3 
(80·4-84·3) 
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Western Europe 
81·6 
(79·4-83·6) 
82·2 
(80·0-84·1) 
81·6 
(79·5-83·6) 
81·8 
(79·8-83·7) 
81·8 
(79·8-83·8) 
81·6 
(79·4-83·6) 
81·8 
(79·7-83·8) 
81·7 
(79·5-83·7) 
82·7 
(80·9-84·5) 
82·0 
(79·9-83·9) 
82·3 
(80·5-84·1) 
83·2 
(81·6-84·7) 
Latin America/ 
Caribbean 
55·0 
(51·2-58·7) 
60·6 
(56·2-65·3) 
55·9 
(52·3-59·5) 
57·8 
(54·3-60·7) 
57·8 
(54·3-61·4) 
55·6 
(51·8-59·3) 
58·2 
(53·8-62·6) 
61·2 
(57·0-65·6) 
68·4 
(63·9-72·7) 
64·8 
(60·1-69·7) 
66·9 
(64·6-69·3) 
81·0 
(79·5-82·5) 
Caribbean 
45·0 
(36·3-54·1) 
46·4 
(37·5-56·1) 
47·2 
(37·5-58·1) 
48·7 
(38·6-59·4) 
46·7 
(37·7-56·5) 
45·4 
(36·7-55·0) 
48·9 
(38·8-57·8) 
53·4 
(46·5-59·4) 
56·3 
(43·5-71·5) 
59·3 
(54·1-64·2) 
58·8 
(51·8-66·0) 
80·7 
(77·9-83·3) 
Central America 
45·4 
(35·9-54·1) 
53·0 
(41·5-62·8) 
46·1 
(36·6-55·2) 
51·7 
(46·4-57·3) 
49·9 
(42·0-57·4) 
46·4 
(37·6-54·7) 
50·1 
(40·5-61·1) 
50·9 
(42·5-58·4) 
66·8 
(58·8-74·3) 
56·0 
(46·8-65·7) 
61·9 
(56·1-66·8) 
81·6 
(79·4-83·5) 
South America 
60·2 
(54·8-64·2) 
65·3 
(59·5-69·7) 
61·1 
(56·0-65·6) 
61·3 
(56·5-64·8) 
62·2 
(56·9-66·9) 
60·5 
(55·2-64·5) 
62·6 
(56·9-67·6) 
66·6 
(61·1-72·5) 
70·0 
(65·2-75·3) 
69·3 
(63·7-74·2) 
69·9 
(66·3-72·5) 
80·7 
(79·0-82·6) 
North America 
83·0 
(81·6-84·4) 
83·8 
(82·4-85·2) 
83·0 
(81·6-84·5) 
83·0 
(81·6-84·5) 
83·1 
(81·7-84·5) 
83·0 
(81·6-84·4) 
83·1 
(81·7-84·5) 
83·0 
(81·6-84·5) 
84·0 
(82·6-85·3) 
83·1 
(81·7-84·5) 
83·5 
(82·2-84·8) 
84·1 
(82·8-85·3) 
Oceania 
64·4 
(58·9-69·2) 
65·3 
(59·5-70·3) 
65·2 
(59·4-70·3) 
66·2 
(60·5-71·3) 
65·8 
(59·9-70·5) 
64·7 
(59·2-69·6) 
65·4 
(59·4-70·5) 
68·5 
(64·1-73·2) 
70·6 
(63·6-76·8) 
70·4 
(66·5-74·6) 
71·1 
(66·4-75·2) 
81·5 
(78·6-84·5) 
Oceania 
(Region) 
19·3 
(6·7-33·3) 
21·6 
(7·4-37·1) 
22·4 
(7·9-38) 
23·6 
(8·1-40·0) 
21·4 
(7·6-36·6) 
20·1 
(7·1-34·2) 
23·0 
(7·6-39·7) 
35·3 
(26·3-45·6) 
35·4 
(11·7-58·2) 
42·1 
(33·2-51·7) 
41·2 
(29·5-53·1) 
78·2 
(72·5-83·7) 
Australia/New 
Zealand 
79·1 
(74·8-83·4) 
79·6 
(75·3-83·7) 
79·2 
(74·9-83·4) 
80·1 
(76·4-83·9) 
80·3 
(76·2-84·4) 
79·3 
(75·0-83·7) 
79·3 
(75·2-83·6) 
79·4 
(75·3-83·7) 
82·1 
(78·5-85·6) 
79·6 
(75·6-83·8) 
80·9 
(77·3-84·5) 
82·6 
(79·7-85·8) 
* Policy interventions are defined in Table 2 
+ Comprehensive 50%/100%: Expand treatment access and improve service delivery to close the gap with mean of HIC by 50%/100% 
